Salm-Reifferscheidt L. Tramadol: Africa's opioid crisis. Lancet 2018;391:19 de mayo. [Ref.ID 102613]

Hirschler B. Regulators flag possible birth defect link to GSK's HIV drug. Reuters Health News 2018:18 de mayo. [Ref.ID 102606]

Anónimo. GSK cuts back operations in Africa. DIA Daily 2018:1. [Ref.ID 102445]

Anónimo. Malaria drug fails in four patients treated In Britain, clinical report shows. DIA Daily 2017:7. [Ref.ID 101385]

Almendrala A. The success of HIV treatment is increasing the risk of drug-resistance. And the threat is growing.. The Huffington Post 2016:1. [Ref.ID 100995]

Anónimo. Vaccin paludique RTS,S/AS01E. Prescrire 2016;36:725-6. [Ref.ID 100886]

Larsen TB, Nielsen PB. Stroke and mortality after atrial fibrillation—a global struggle. Lancet 2016;388:1131-2. [Ref.ID 100749]

Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, Commerford P, Jansky P, Avezum A, Sigamani A, Demasceno A, Reilly P, Grinvalds A, Nakamya J, Aje A, Almahmeed W, Moriarty A, Wallentin L, Yusuf S, Connolly SJ, on behalf of the RE-LY Atrial Fibrillation Registry and Cohort Study Investigators. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet 2016;388:1161-9. [Ref.ID 100676]

Diacon AH, van der Merwe L, Barnard M, von Groote-Bidlingmaier F, Lange C, García-Basteiro AL, Sevene E, Ballell L, Barros-Aguirre D. ß-lactams against tuberculosis — New trick for an old dog?. N Engl J Med 2016;375:393-4. [Ref.ID 100492]

González R, Sevene E, Jagoe G, Slutsker L, Menéndez C. A public health paradox: the women most vulnerable to malaria are the least protected. PLOS Medicine 2016:3 de mayo. [Ref.ID 100350]

Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med 2016;14:10. [Ref.ID 100346]

Anónimo. GSK conducting internal review of bribery allegations In Yemen. DIA Daily 2016:1. [Ref.ID 100120]

Anónimo. What next for the malaria RTS,S vaccine candidate?. Lancet 2015;386:1708. [Ref.ID 99666]

Maurice J. And then there were two…polio-endemic countries. Lancet 2015;386:1521-2. [Ref.ID 99659]

Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Hossmann S, Kondé GN, Soumah A, Trelle S, Vicari AS, Watson CH, Kieny MP, Rottingen J-A. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015;386:857-66. [Ref.ID 99512]

Anónimo. An ebola vaccine: first results and promising opportunities. Lancet 2015;386:830. [Ref.ID 99511]

RTS S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015;386:31-45. [Ref.ID 99329]

Moorthy VS, Okwo-Bele J-M. Final results from a pivotal phase 3 malaria vaccine trial. Lancet 2015;386:5-7. [Ref.ID 99327]

Anónimo. Malaria vaccine receives approval from European regulators nearly 30 years after initial development. DIA Daily 2015:1. [Ref.ID 99259]

Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J. Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf 2015;38:565-75. [Ref.ID 99239]